Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·

The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells

Publication files not online:

Author: Leeuw van Weenen, J.E. de · Parlevliet, E.T. · Maechler, P. · Havekes, L.M. · Romijn, J.A. · Ouwens, D.M. · Pijl, H. · Guigas, B.
Institution: TNO Kwaliteit van Leven
Source:Biochemical Pharmacology, 12, 79, 1827-1836
Identifier: 408475
Keywords: Biology · Biomedical Research · α2-Adrenergic receptor · Bromocriptine · Dopamine receptor · INS-1E cells · Insulin secretion · Mice · alpha 2 adrenergic receptor · bromocriptine · cyclic AMP · domperidone · dopamine 2 receptor stimulating agent · G protein coupled receptor · glucose · insulin · placebo · yohimbine · analytic method · animal cell · animal experiment · article · cell line · cell membrane depolarization · cell membrane potential · controlled study · drug effect · glucose clamp technique · glucose tolerance test · hyperglycemia · in vitro study · in vivo study · inhibition kinetics · insulin release · male · mouse · nonhuman · pancreas islet beta cell · priority journal · Western blotting · Animals · Bromocriptine · Cell Line · Dopamine Agonists · Dose-Response Relationship, Drug · Glucose · Insulin · Insulin-Secreting Cells · Insulinoma · Male · Mice · Mice, Inbred C57BL · Rats · Receptors, Adrenergic, alpha · Receptors, Dopamine D2


Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic features in obese patients with type 2 diabetes by a still unknown mechanism. In the present study, we investigated the acute effect of bromocriptine and its underlying mechanism(s) on insulin secretion both in vivo and in vitro. For this purpose, C57Bl6/J mice were subjected to an intraperitoneal glucose tolerance test (ipGTT) and a hyperglycemic (HG) clamp 60. min after a single injection of bromocriptine or placebo. The effects of bromocriptine on glucose-stimulated insulin secretion (GSIS), cell membrane potential and intracellular cAMP levels were also determined in INS-1E beta cells. We report here that bromocriptine increased glucose levels during ipGTT in vivo, an effect associated with a dose-dependent decrease in GSIS. During the HG clamp, bromocriptine reduced both first-phase and second-phase insulin response. This inhibitory effect was also observed in INS-1E beta cells, in which therapeutic concentrations of bromocriptine (0.5-50. nM) decreased GSIS. Mechanistically, neither cellular energy state nor cell membrane depolarization was affected by bromocriptine whereas intracellular cAMP levels were significantly reduced, suggesting involvement of G-protein-coupled receptors. Surprisingly, the DRD2 antagonist domperidone did not counteract the effect of bromocriptine on GSIS, whereas yohimbine, an antagonist of the α2-adrenergic receptors, completely abolished bromocriptine-induced inhibition of GSIS. In conclusion, acute administration of bromocriptine inhibits GSIS by a DRD2-independent mechanism involving direct activation of the pancreatic α2-adrenergic receptors. We suggest that treatment with bromocriptine promotes beta cells rest, thereby preventing long-lasting hypersecretion of insulin and subsequent beta cell failure. © 2010 Elsevier Inc.